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Purpose: To complete the baseline trachoma map worldwide by conducting population-based surveys in an
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Methods: A series of national and sub-national projects owned, managed and staffed by ministries of health,
conduct house-to-house cluster random sample surveys in evaluation units, which generally correspond to
‘‘health district’’ size: populations of 100,000–250,000 people. In each evaluation unit, we invite all residents
aged 1 year and older from h households in each of c clusters to be examined for clinical signs of trachoma,
where h is the number of households that can be seen by 1 team in 1 day, and the product h c is calculated to
facilitate recruitment of 1019 children aged 1–9 years. In addition to individual-level demographic and clinical
data, household-level water, sanitation and hygiene data are entered into the purpose-built LINKS application
on Android smartphones, transmitted to the Cloud, and cleaned, analyzed and ministry-of-health-approved via
a secure web-based portal. The main outcome measures are the evaluation unit-level prevalence of follicular
trachoma in children aged 1–9 years, prevalence of trachomatous trichiasis in adults aged 15 + years, percentage
of households using safe methods for disposal of human feces, and percentage of households with proximate
access to water for personal hygiene purposes.
Results: In the first year of fieldwork, 347 field teams commenced work in 21 projects in 7 countries.
Conclusion: With an approach that is innovative in design and scale, we aim to complete baseline mapping of
trachoma throughout the world in 2015.
Keywords: Blindness, mHealth, prevalence study, trachoma, trichiasis
INTRODUCTION
The World Health Assembly has set the year 2020 as
the target for global elimination of trachoma as a
public health problem.1 Mapping is a critical first
stage for the elimination of trachoma because pro-
grams determine the need for interventions based
on population-level prevalence of disease.2
The geographical burden of trachoma has only been
partially assessed3; from 1987 to the beginning of
2012, population-based surveys mapped trachoma in
1115 districts worldwide, with data thought to be
required from at least another 1238 suspected ende-
mic districts4 to complete the global picture (Figure 1).
At a minimum, trachoma mapping involves gen-
eration of prevalence data on the clinical signs
FIGURE 1. Scale of the Global Trachoma Mapping Project.
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follicular trachoma (TF) in children aged 1–9 years,
and trachomatous trichiasis (TT) in adults aged
15 + years. In endemic communities, a person is
considered to have TF when there are five or more
follicles, each at least 0.5 mm in diameter, in the
central part of the upper tarsal conjunctiva.5 TF is
associated with conjunctival Chlamydia trachomatis
infection,6 and is most common in children.7,8 In
those same communities TT is the presence of at least
one eyelash touching the eyeball or evidence of recent
removal of in-turned eyelashes;5 it occurs more
frequently with increasing age9,10 and disproportion-
ately affects women.7,10–12 To generate baseline data
for program use, the World Health Organization
(WHO) recommends cluster random sample surveys,
using 20–30 clusters.2 In general, the evaluation unit is
the district, which for trachoma control purposes
WHO defines as ‘‘the normal administrative unit for
health care management, consisting of a population
unit between 100,000–250,000 persons.’’2 In contexts
in which trachoma is expected to be highly and
widely endemic, evaluation units can be constructed
to encompass larger populations than this, in order to
allow control programs to commence.13
In populations in which TF prevalence in
1–9-year-olds is 30%, WHO recommends the
SAFE strategy (surgery, antibiotics, facial cleanliness,
environmental improvement) for elimination be
implemented for at least 5 years before TF preva-
lence is estimated again.13 Therefore, mapping must
be completed by 2015 to allow programs to complete
at least one phase of interventions in high prevalence
areas before the 2020 elimination target date. The
Global Trachoma Mapping Project (GTMP) began
formal operations on 23 July 2012 and commenced
fieldwork on 17 December 2012, with the aim of
mapping all remaining suspected endemic districts
by the end of 2015.
This paper describes the process of methodological
development, and the methodology itself.
MATERIALS AND METHODS
Advisory Committee and Working Groups
A committee established in March 2012 by the
International Trachoma Initiative14 to outline the
issues surrounding global trachoma mapping was
asked by Sightsavers, the GTMP grant manager, to
serve as an Advisory Committee to the GTMP. The
four working groups of that committee (Table 1)
TABLE 1. Working groups for the Global Trachoma Mapping Project.
Name of working group Goals
Methodologies (1) To produce guidelines for when to use each of the current protocols for determining the need for
intervention against trachoma, i.e.,
(a) at district level (trachoma rapid assessment,39 population-based prevalence surveys,2 and
integrated threshold mapping19).
(b) at larger-than-district level (trachoma rapid assessment,39 population-based prevalence
surveys,2 and integrated threshold mapping19).
(2) To review current indicators and protocols for collecting data on water, sanitation and hygiene (WASH)
variables, and see to what extent they could be practically integrated with the protocols considered in (1).
Prioritization (1) Prioritize countries for baseline trachoma mapping.
(2) Prioritize (in collaboration with in-country opinion leaders and other stakeholders) districts for baseline
trachoma mapping within each country.
(3) Identify opportunities to coordinate with other mapping efforts.
Tools (1) Review available systems for data collection, validation, storage, analysis and sharing in projects
originating with fieldwork conducted in rural communities of developing countries.
(2) Recommend (to the Advisory Committee) the most appropriate systems for use in baseline trachoma
mapping, bearing in mind the separate needs of mapping efforts that collect:
(a) data relevant only to trachoma control,
(b) data relevant to control of trachoma and other endemic diseases, and
(c) data relevant to control of one or more endemic diseases and WASH programs.
Training (1) Review current systems and materials for training teams to undertake protocols that estimate the need
for intervention against trachoma, including those in which such estimates are collected at the same time
as estimates of the prevalence of other endemic diseases and/or WASH variables.
(2) Review current systems and materials for training the trainers who will train the teams described in (1),
including materials to develop trainers’ training skills.
(3) Recommend (to the Advisory Committee) the most appropriate training methods for use in baseline
trachoma mapping, bearing in mind the separate training needs of mapping efforts that collect:
(a) data relevant only to trachoma control,
(b) data relevant to control of trachoma and other endemic diseases, and
(c) data relevant to control of one or more endemic diseases and WASH programs.
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were requested to continue to develop ideas and
provide input to the Advisory Committee. A chief
scientist (AWS) was appointed to collate advice
from the working groups and make final recom-
mendations to the Advisory Committee on strategies
to adopt.
Project Structure and Ownership
The GTMP is constructed as a series of administra-
tively separate projects with a common methodology,
generally operating at the national level. In Ethiopia
and Nigeria, where it was believed at the time of
project launch that 434 and 209 districts, respectively,
required mapping,4 projects are being implemented
at regional state level (Ethiopia) and state level
(Nigeria).
As the central objective of the GTMP is to generate
data for use by trachoma elimination programs,
government ownership of mapping is essential.
Without this, the data that it generates are less likely
to be acted upon locally. This philosophy has
influenced a number of key project decisions (Table 2).
Prioritization
Highly-burdened endemic countries need rapid scale-
up of trachoma elimination activities and are being
prioritized by the GTMP. The level of local prepared-
ness to undertake mapping and to implement SAFE
interventions after mapping is also important to the
prioritization process; commencing work in countries
ready to collect data and use them for programmatic
decision making allowed us to make rapid early
progress.
Training of Field Teams
We developed standardized training material for
trachoma graders and data recorders. We compiled a
draft training system (comprising a trainers’ manual,
a series of slide sets and Microsoft Excel-based kappa
score calculators) by assembly and adaptation of a
range of materials used previously, plus generation of
some entirely new resources, then field-tested it at a
developmental training week in Oromia, Ethiopia,
from 8–12 October 2012, involving 15 field teams. We
incorporated lessons learned into subsequent revi-
sions. We also developed a training-of-trainers
package.
GTMP field teams are each composed of one
trachoma grader and one data recorder, plus a
driver and a local guide. Graders and recorders are
recruited (against standard selection requirements,
Figure 2) by the local ministry of health, then trained
using GTMP materials15 over 5 days. The first 2
training days are an intensive classroom- and field-
based training and testing period for prospective
graders, labeled the ‘‘grader qualifying workshop.’’ In
the fieldwork component, we provide one grader
trainer for every four grader trainees to make effective
patient-based instruction possible. Only grader trai-
nees who pass slide- and field-based tests of diagnos-
tic accuracy (see below), and those recorder trainees
who pass an electronically-marked test on the accur-
acy of their data capture, graduate to become mem-
bers of the survey team.
TABLE 2. Efforts to maximize government ownership within the Global Trachoma Mapping Project.
Domain Approach to facilitate government ownership
Stakeholder engagement Initial engagement with ministry of health is preferably made in conjunction with a non-governmental
organization already collaborating with the ministry.
Field team composition Grader and recorder trainees are selected, recruited and contracted by the ministry of health.
Field team training Field team training is conducted under the auspices of the ministry of health, using (as far as is practical)
national trainers.
Capacity building Ministry of health staff draft the evaluation unit divisions, cluster list and fieldwork protocol, which is
then refined and finalized in discussion with Global Trachoma Mapping Project epidemiologists to
ensure international standardization. The ministry of health appoints a lead author to draft a paper
presenting the project results for publication in a peer-reviewed journal.
Data management Although (in order to ensure international standardization) data cleaning is undertaken by a single data
manager who works across all projects, the adequacy of data collection and data cleaning process must
be approved by a designated ministry of health official before analysis. Prevalence estimates must be
approved by a designated ministry of health official before they are considered finalized. Only the
ministry of health has access to download the full datasets. Only prevalence categories (not the
estimates themselves) are released to the Global Atlas of Trachoma, and only after ministry of health
approval. The ministry of health is free to share data with its partners at any time.
Global Trachoma Mapping Project 217
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In an effort to ensure consistency of grading, we
established a 3-level grader training and certification
cascade:
(1) Each GTMP master grader (initially ABK, AWS,
CM and WA) has experience delivering clinical
teaching at post-graduate level; experience of
previous trachoma surveys as a grader or super-
visor; a kappa statistic 0.80 against the chief
scientist for diagnosis of TF in children in live-
subject inter-grader agreement (IGA) tests; and
participation as a trainer in at least 2 grader
qualifying workshops.
(2) To be certified as GTMP grader trainers, individ-
uals need experience delivering clinical teaching
at post-graduate level or experience of previous
trachoma surveys as a grader or supervisor; a
kappa statistic 0.80 against a GTMP master
grader for diagnosis of TF in children in a live-
subject IGA test; and participation as a trainee in
at least one grader qualifying workshop.
(3) To be certified as GTMP graders, individuals need
a medical or nursing background or equivalent
experience; a kappa statistic 0.70 against a
GTMP grader trainer for diagnosis of TF in
children in a live-subject IGA test; and participa-
tion as a trainee in at least one grader qualifying
workshop.
The master graders have all been extensively
involved in the development and/or delivery of
the GTMP under the oversight of the chief scientist,
and understand it thoroughly. They train grader
trainers using the full training package, incorporat-
ing some teaching about teaching, preparing grader
trainers who pass the IGA test against a master
grader to then go on and deliver training to candi-
date graders in their own projects. Materials and
methods to be used for all training activities are
clearly outlined.
Before progressing to a live-subject IGA test,
prospective grader trainers and graders must pass a
slide-based IGA test using a set of 50 slides, on each of
which the presence or absence of TF has been
unanimously agreed by five internationally recog-
nized trachoma graders (ABK, AWS, HRT, TML, WA).
Live-subject IGA tests require 50 children aged 1–9
years, of whom ideally a minimum of 15 and a
maximum of 35 have TF, as determined by the
reference grader for the test. If fewer than 15 or
more than 35 subjects have TF, the test is not invalid,
but becomes more difficult to pass, since the kappa
statistic heavily penalizes mis-calls when the fre-
quency of the outcome of interest is very low or very
high in the test sample. Countries with suspected low
TF prevalence send candidate grader trainers (and in
some cases, candidate graders) to highly endemic
countries for training and certification. To avoid
incorrect estimation of diagnostic agreement because
of between-eye correlation of clinical phenotype,16
only one eye of each child is examined by those taking
the IGA test.
Both grader and recorder trainees should: 
• Know how to interact well with residents of rural communities. This means some fluency in the local 
language, an understanding of the importance of greetings, and good inter-personal communication with 
village leaders, individuals being examined and their families.  
• Be able to walk long distances and work long hours in the field.  
• (Depending on the method of household selection) be able to do (mathematical) division. 
Grader trainees should: 
• Have some clinical training. (Individuals with previous experience grading trachoma may be easier to train 
than those without experience, but grader trainers must equally be prepared to “un-train” bad grading habits 
if necessary. Individuals with ophthalmic experience may take less time than individuals without 
ophthalmic experience to demonstrate proficiency in everting an eyelid without touching the cornea.)  
• Have good near vision, using presbyopic spectacles if needed.  
• Be informed in advance that the first 2 days of training are a grader qualifying workshop, and that not all 
will score well enough to qualify as trachoma graders for survey work. 
Recorder trainees should: 
• Be able to read and write. 
• Have excellent attention to detail.  
• Not necessarily be health care personnel; hiring young people who are familiar with the use of smartphones 
may be a better option.
FIGURE 2. Selection criteria for Global Trachoma Mapping Project (GTMP) field team trainees.15
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Survey Sampling Approach and Sample Size
A reliable survey methodology was essential to the
aims of the project. A number of survey methods have
previously been used to map trachoma, including
trachoma rapid assessment, acceptance sampling
trachoma rapid assessment, cluster random sampling
and integrated threshold mapping (ITM).17–19 We did
not consider the first two methods as they do not
provide prevalence estimates. To compare cluster
random sampling and ITM, computer-based simula-
tions were undertaken in order to investigate ITM’s
utility as a possible trachoma mapping approach in
areas where mapping of other diseases was also
required. Both the simulations20 and multi-country
data analyses21 suggest that ITM will systematically
under-estimate trachoma prevalence, with the extent
of underestimation proportional to the degree of bias
introduced by school-based sampling. This results in
greater likelihood of misclassification at the evalu-
ation unit level when the true prevalence is close to a
treatment decision threshold.20 For each evaluation
unit, therefore, the GTMP uses a 2-stage cluster
random sample survey.2 Where evaluation units are
larger than districts, first-stage clusters are selected in
proportion to constituent district population size.
Further specifics of cluster sampling depend on local
geopolitical divisions and community population
structure. GTMP epidemiologists work with minis-
tries of health to construct a bespoke sampling
framework for each project, which, to the extent
possible, follows the principles of equal probability
random sampling.
The survey sample size in each evaluation unit is
based on an expected TF prevalence in 1–9-year-olds
of 10%, since this is the most critical threshold for
programmatic decision making. Evaluation units in
which the baseline TF prevalence in 1–9-year-olds is
10% or above qualify for annual single-dose azithro-
mycin treatment of the entire population for at
least 3 years, whereas those with a TF prevalence in
1–9-year-olds of510% do not.2 According to the
single population proportion for precision formula,22
if the expected TF prevalence is 10% and we wish to
have 95% confidence of estimating the true prevalence
with absolute precision of 3%, 384 children aged 1–9
years selected by simple random sampling would be
required. Assuming a cluster size of 50 children, the
design effect is estimated at 2.65 (based on previous
trachoma prevalence surveys: Beatriz Mun˜oz, unpub-
lished data), so 1019 children are needed. Inflating
this figure by a factor of 1.2 to account for non-
response, we sample a sufficient number of house-
holds in each evaluation unit for 1222 children aged
1–9 years to be resident therein.
The approach to household selection within clus-
ters varies from country to country, and will be
described in the forthcoming series of papers
containing country-specific results. In each setting,
however, to avoid convenience sampling by field
teams anxious to ensure that a minimum number of
children are examined in the course of a day’s work,
we prescribe a fixed number of households to be
enrolled per cluster, based on the number of house-
holds (generally 30) that a team should be able to
complete in a day. The number of clusters per
evaluation unit for each context is determined by
dividing 1222 by the product of the number of
households per cluster and the mean number of 1–9-
year-olds in each household, with the latter derived
from best available census data. The minimum
number of clusters per evaluation unit is 20.2
Although we also aim to estimate TT prevalence in
15-year-olds, sample sizes have been calculated
based only on parameters relating to TF in children;
the low prevalence of TT (nearly always52% in
adults except in the most hyperendemic areas) means
that accurately estimating its prevalence requires
substantially larger samples. Having determined the
number of households required to recruit sufficient
children to estimate TF prevalence as above, the
sample of 15-year-olds used for estimating TT
prevalence is set as the adults living in those same
households. We accept the loss of precision in the
estimate of TT prevalence inherent in this approach.
Because of the link between environmental hygiene
parameters and trachoma,23 household-level water,
sanitation and hygiene (WASH) variables (Table 3) are
included in the GTMP data collection package.
Field Methodology
In selected households, we could either invite all
resident 1–9-year-olds and all resident 15-year-olds
to participate in the survey, or invite all residents over
the age of 1 year to participate. We are doing the
latter because it is considerably easier to explain to
communities, and allows for more complete data on
TT to be collected.
The head of each household is greeted, and the
purpose and conduct of the survey explained in the
local language. If the household head consents to
participate, global positioning system (GPS) coordin-
ates are collected from outside the front door of the
house or compound, and the WASH questions asked
of the household head or their proxy. A visual
inspection of the household latrine and hand-washing
facilities, if present, follows (Table 3).
All data capture is electronic, using a purpose-built
Open Data Kit-based Android smartphone applica-
tion (LINKS, Task Force for Global Health, Atlanta,
GA, USA; https://linkssystem.org/24). Android-
based technology is suitable for large-scale trachoma
surveys, and compared to standard paper question-
naires, saves time, is preferred by data recorders and
Global Trachoma Mapping Project 219
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TABLE 3. Water, sanitation and hygiene data collected at each household included in surveys for the Global Trachoma Mapping
Project,.
Question Possible responses
In the dry season, what is the main source of drinking water for members of
your household?
01 = Piped water into dwelling
02 = Piped water to yard/plot
03 = Public tap/standpipe
04 = Tubewell/borehole
05 = Protected dug well
06 = Unprotected dug well
07 = Protected spring
08 = Unprotected spring
09 = Rainwater collection
10 = Water vendor
11 = Surface water (e.g. river, dam, lake, canal)
99 = Other (specify)
How long does it take to go there, get water, and come back? 1 = Water source in the yard
2 = Less than 30 minutes
3 = Between 30 minutes and 1 hour
4 = More than 1 hour
In the dry season, what is the main source of water used by your household
for washing faces?
01 = Piped water into dwelling
02 = Piped water to yard/plot
03 = Public tap/standpipe
04 = Tubewell/borehole
05 = Protected dug well
06 = Unprotected dug well
07 = Protected spring
08 = Unprotected spring
09 = Rainwater collection
10 = Water vendor
11 = Surface water (e.g. river, dam, lake, canal)
99 = Other (specify)
If you collected water there to bring back to the house, how long would it
take to go there, get water, and come back?
0 = All face washing done at water source
1 = Water source in the yard
2 = Less than 30 minutes
3 = Between 30 minutes and 1 hour
4 = More than 1 hour
Where do you and other adults in the household usually defecate? 1 = Shared or public latrine
2 = Private latrine
3 = No structure, outside near the house
4 = No structure, in the bush or field
9 = Other
Ask to see the latrine/toilet.
Observation:
What kind of toilet facility do the adults in the household use?
01 = Flush/pour flush to piped sewer system
02 = Flush/pour flush to septic tank
03 = Flush/pour flush to pit latrine
04 = Flush/pour flush to open drains
05 = Flush/pour flush to unknown place
06 = Ventilated improved pit latrine
07 = Pit latrine with slab
08 = Pit latrine without slab/open pit
09 = Composting toilet
10 = Bucket
11 = Hanging toilet/hanging latrine
12 = No facilities or bush or field
99 = Other (specify)
Observation: Is there a handwashing facility within 15 m of the latrine/toilet? 0 = No
1 = Yes
5 = Not applicable (no latrine/toilet)
Observation: At the time of the visit, is water available at the handwashing
facility?
0 = No
1 = Yes
5 = Not applicable (no handwashing facility)
Observation: At the time of the visit, is soap or ash available at the
handwashing facility?
0 = No
1 = Yes
5 = Not applicable (no handwashing facility)
220 A. W. Solomon et al.
Ophthalmic Epidemiology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 L
on
do
n]
 at
 03
:35
 22
 Se
pte
mb
er 
20
15
 
is more accurate.25 GPS data permit verification that
field teams have visited randomly selected clusters,
even when remote and difficult to access. Data are
stored on the smartphone’s micro-secure digital (SD)
card, allowing retention until a data-enabled mobile
network or WiFi signal is available, and recovery in
nearly all instances of phone failure or destruction.
Consenting individuals are examined by GTMP-
certified graders for the signs TT, TF and intense
trachomatous inflammation (TI) of the WHO simpli-
fied trachoma grading scheme,5 using 2.5magnify-
ing binocular loupes, and sunlight or a torch for
illumination.2 To prevent pathogen carry-over
between successive subjects, graders clean their
hands with alcohol-based hand gel after each
examination.
Households in which one or more resident 1–9-
year-olds are missing at the time of the survey
team’s first visit are re-visited wherever possible at
the end of the day. The scale of the GTMP does not
allow for repeat visits to households with other
missing data.
Ethical Considerations
Trachoma mapping is the mandate of ministries of
health, who consider it part of routine surveillance
activities rather than a research activity. For this
reason, and because in the largely non-literate rural
populations among whom these surveys are con-
ducted, verbal consent is generally more acceptable
than written consent, we request informed verbal
consent for eye examination from each resident, or in
the case of minors, from their parent or legal guard-
ian. Consent is documented in the LINKS application.
Examination for TT is benign. Eversion of the
tarsal conjunctivae to allow examination for TF and
TI causes only minimal transient discomfort.
Following WHO recommendations,26 young children
are held by their mother or a community assistant to
ensure that they are able to keep still during the
examination. This prevents accidental injury to the
eye and ensures the process is as quick and as
minimally distressing as possible.
TF is generally most common in pre-school-age
children, while the prevalence of TT increases with
age. Therefore, it is particularly important to ensure
that young children and the elderly are proportion-
ately represented in returned survey data. Because
people with disabilities or mental health issues are
more likely than others to be socioeconomically
disadvantaged, and trachoma is associated with
poverty,27 we try to ensure that such individuals are
not excluded from participating.
The project was approved by the ethics committee
of the London School of Hygiene & Tropical Medicine
(reference number 6319), and the appropriate local
ethics committee identified by each ministry of health.
The work conforms to the guidelines of the
Declaration of Helsinki.
Treatment
All individuals with active trachoma identified
during the surveys are offered 1% tetracycline eye
ointment to apply twice daily for 6 weeks, while those
with trichiasis are referred to the nearest health
facility designated to provide TT surgery.
Supervision
A supervisor (either an ophthalmologist or senior
ophthalmic nurse) is appointed for every 7–10 teams,
spending at least 1 day per fortnight in the field with
each team to provide in-service feedback and sup-
portive supervision of diagnostic accuracy, as well as
other technical, logistic and pastoral assistance as
required.
Data Upload, Storage and Access
Data are uploaded (when the phone connects with a
cellular or WiFi network) to a Cloud-based server,
with 128-bit encryption applied at the transport layer.
The connection uses TLS 1.2; is encrypted and
authenticated using AES_128_GCM, with DHE_RSA
as the key exchange mechanism. Subsequent inter-
actions with data (Figure 3) take place only through a
secure website (transport layer security, IP-restricted
firewall, and site authentication and authorization),
with each project walled off from others and access-
ible only via password-protected individual login.
Personally identifiable data are available only to
nominated personnel at the relevant ministry of
health and one GTMP-dedicated, Atlanta-based data
manager, with only ministry of health nominees
having the ability to download complete datasets. To
provide standardization of data cleaning across pro-
jects, only the data manager is able to make changes
to the data, all of which are logged.
Data Approvals and Analysis
Data are checked and cleaned by the data manager
each weekday, with queries being resolved through
dialogue with field teams. The cleaned dataset is then
available for electronic review by a designated indi-
vidual at the ministry of health, who is first asked to
approve the adequacy of data collection and the
appropriateness of any cleaning that has been under-
taken (‘‘approval c’’, Figure 3).
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Data are then analyzed in R (R Foundation for
Statistical Computing, Vienna, Austria) and
Structured Query Language (SQL) using automated
algorithms. For each cluster, the proportion of
1–9-year-olds with TF is adjusted by weighting the
proportion of each 1-year age band observed to have
TF by the proportion of the local 1–9-year-old popu-
lation expected to have that age, according to the most
recent census. Similarly, for each cluster, the propor-
tion of 15-year-olds with TT is adjusted by weight-
ing the proportion of each sex-specific 5-year age
band observed to have TT by the proportion of the
local 15-year-old population expected to have that
age and sex. These adjustments are intended to
compensate for non-random differences in examin-
ation availability between different age groups and
sexes, which would otherwise tend to systematically
bias prevalence estimates; the very young and very
old are less mobile and more likely to have TF and TT
respectively. Then, because field teams are instructed
to examine all residents of a set number of households
in each cluster, to prevent clusters in which greater
numbers are examined having greater influence on
the calculated prevalence, the mean of the adjusted
cluster-level TF proportions is taken as the evaluation
unit-level prevalence of TF, and the mean of the
adjusted cluster-level TT proportions is taken as the
evaluation unit-level prevalence of TT.28
Analyzed data are then approved for release by a
designated individual at the ministry of health
(‘‘approval p’’, Figure 3). This approval results in
automatic upload29 of evaluation unit-level preva-
lence categorization to the open access Trachoma
Atlas30 (www.trachomaatlas.org), as well as produc-
tion of summary reports for the ministry. Data are
easily fed into the Trachoma Action Planning pro-
cess,31 facilitating rapid programmatic decision-
making.
RESULTS
Arabic, English, French, Portuguese and Spanish
versions of the training package15 (consisting of a
trainer’s manual, 13 accompanying Microsoft
PowerPoint presentations and 3 Microsoft Excel
spreadsheets) have been produced. Using these
materials, in the first year of fieldwork (17 December
2012–16 December 2013), 347 field teams were trained
for and deployed in 21 projects in 7 countries:
Ethiopia, Laos, Malawi, Mozambique, Nigeria,
Solomon Islands and Yemen.
DISCUSSION
A complete understanding of the geographical distri-
bution and intensity of disease endemicity worldwide
is key to the elimination of blinding trachoma. Roll-
out of a mapping methodology that is internationally
standardized in its epidemiological approach, training
cascade and data handling standards, as we are
FIGURE 3. Global Trachoma Mapping Project (GTMP) data handling and flow. (1) The field team upload the raw data, which are
available for review and download by designated ministry of health (MOH) personnel. (2) The GTMP Data Manager cleans the raw
data by checking for and querying (with the field team) any errors, internal inconsistencies or missing data. (3) A designated MOH
official evaluates the cleaned dataset, and then either approves it (‘‘approval C’’) or queries it; once approved, analyses to generate
evaluation unit-level prevalences are run automatically. (4) A designated MOH official evaluates the prevalence figures and either
approves them (‘‘approval P’’) or queries them. (5) Once approved, categorical prevalence data are uploaded to the Global Atlas of
Trachoma (GAT).
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undertaking in the GTMP, permits relatively rapid
scale-up of mapping and promotes confidence in the
internal comparability of the data. There is little doubt
among project partners that Android-based data
capture, Cloud-based storage and secure online
approval are considerable improvements on the
paper-based data collection systems of trachoma
surveys completed in years past.
On the analytical side, we believe that our adjust-
ment algorithms lead to more robust estimates of
trachoma prevalence than have been reported in the
majority of previous surveys. In particular, because
TT is more common in the elderly and the elderly are
more likely to be found at home than are young
adults, age-adjustment means that estimates of the
trichiasis ‘‘backlog’’ are significantly reduced
(by450% in some locations) as a result of adjustment.
The practical consequence of this is that elimination
programs are less likely to end up searching for TT
cases that do not actually exist. We recognize, though,
that even with adjustment for recruitment of specific
age groups, prevalence estimates can be biased
upwards or downwards by differential attendance of
those with TF or TT. Our methods for encouraging
high survey attendance minimize but do not negate
this bias.
A number of decisions on methodologies to be
used for the GTMP were controversial, even within
the group of experts who provided advice on their
development – the authors of this paper. These issues
were discussed at length within working groups and
the Advisory Committee. First, we are training teams
to record data on only three of the five signs of the
WHO simplified trachoma grading system,5 having
excluded trachomatous scarring (TS) and corneal
opacity (CO). We have done so because there is no
specific program response to the observation of high
prevalence of either of these signs, and this project is
focused on providing baseline data for initiation of
elimination activities. TI and TT usually have low
prevalence, so we do not attempt to demonstrate
inter-grader agreement for these signs. We do not
currently intend to generate a prevalence estimate for
TI, and are collecting data on this sign principally to
prevent graders being tempted to flag conjunctival
inflammation as ‘‘TF’’ in the absence of five central
follicles,5 and, to a lesser extent, as an insurance policy
against potential future changes in guidelines for
monitoring program impact. The main outcome
measure is the prevalence of TF in 1–9-year-olds at
evaluation unit-level, which is the current indicator to
determine whether A, F and E aspects of the SAFE
strategy should be implemented. Second, we are not
training teams to record data on the presence or
absence of signs of an ‘‘unclean face.’’ We recognize
the likely importance of keeping children’s faces clean
for reducing transmission of ocular C. trachomatis
infection,32 but the definition of an unclean face for
survey purposes is controversial, and the reproduci-
bility of its observation has been questioned.33–36
Third, an initial goal, obtaining unanimous agreement
on the list of household-level WASH questions,
proved elusive. There are a variety of established
instruments used for assessing WASH coverage,
among which there is considerable overlap but also
considerable diversity. Our questions are essentially a
subset of those from the WHO/UNICEF Joint
Monitoring Program (JMP) household question-
naire,37 adapted (with as light a touch as possible) to
the specific interests of trachoma control programs.
We chose the JMP questionnaire because it is the
established metric for measuring progress towards
the Millennium Development Goals, and is widely
used by national governments to estimate national
water and sanitation coverage. However, JMP data do
not accurately estimate coverage in sub-national
administrative areas and so may be less useful in
guiding effective trachoma control. We hope that our
data can validate or challenge other estimates of
WASH coverage, such as recent work using house-
hold survey data and spatial statistics,38 and thereby
help determine where particular investment in WASH
interventions is needed to hasten trachoma
elimination.
Despite these issues that have generated debate, we
have a collective confidence in the relevance and
robustness of our approach, and with our many
partners are generating the momentum necessary to
complete the global trachoma map. We look forward
to the GTMP’s completion, at which point we will be
able to understand the true scale of the task required
to eliminate trachoma as a public health problem
worldwide.
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